{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T09:57:28Z","timestamp":1781863048303,"version":"3.54.5"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82574790"],"award-info":[{"award-number":["82574790"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Natural Science Foundation of Shandong Province","award":["ZR2023LZY002"],"award-info":[{"award-number":["ZR2023LZY002"]}]},{"name":"Shandong Provincial Taishan Scholar Youth Expert Program","award":["tsqn 202312374"],"award-info":[{"award-number":["tsqn 202312374"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"DOI":"10.1186\/s40164-026-00803-2","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T09:30:16Z","timestamp":1781861416000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical research progress of menin inhibitors for acute myeloid leukemia: latest updates from the 2025 ASH Annual Meeting"],"prefix":"10.1186","volume":"15","author":[{"given":"Chenchen","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"803_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/JCO.24.00826","volume":"43","author":"GC Issa","year":"2025","unstructured":"Issa GC, Aldoss I, Thirman MJ, DiPersio J, Arellano M, Blachly JS, et al. Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101). J Clin Oncol. 2025;43:75\u201384. https:\/\/doi.org\/10.1200\/JCO.24.00826.","journal-title":"J Clin Oncol"},{"key":"803_CR2","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1182\/blood.2025028357","volume":"146","author":"ML Arellano","year":"2025","unstructured":"Arellano ML, Thirman MJ, DiPersio JF, Heiblig M, Stein EM, Schuh AC, et al. Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study. Blood. 2025;146:1065\u201377. https:\/\/doi.org\/10.1182\/blood.2025028357.","journal-title":"Blood"},{"key":"803_CR3","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1200\/JCO-25-01694","volume":"43","author":"ES Wang","year":"2025","unstructured":"Wang ES, Montesinos P, Foran J, Erba H, Rodriguez-Arboli E, Fedorov K, et al. Ziftomenib in relapsed or refractory NPM1-mutated AML. J Clin Oncol. 2025;43:3381\u201390. https:\/\/doi.org\/10.1200\/JCO-25-01694.","journal-title":"J Clin Oncol"},{"key":"803_CR4","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1182\/blood-2025-3418","volume":"146","author":"M Arellano","year":"2025","unstructured":"Arellano M, Thirman M, DiPersio J, Heiblig M, Stein E, Schuh A, et al. Revumenib for patients with relapsed or refractory (R\/R) Nucleophosmin 1\u2013mutated (NPM1m) acute myeloid leukemia (AML): outcomes by prior treatment in the phase 2 AUGMENT-101 study. Blood. 2025;146:3418\u20133418. https:\/\/doi.org\/10.1182\/blood-2025-3418.","journal-title":"Blood"},{"key":"803_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1182\/blood-2025-47","volume":"146","author":"W-Y Jen","year":"2025","unstructured":"Jen W-Y, DiNardo C, Short N, Farhat A, El Hajjar G, Zhang B, et al. Phase II Study of the all-oral combination of revumenib (SNDX-5613) with decitabine\/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML. Blood. 2025;146:47\u201347. https:\/\/doi.org\/10.1182\/blood-2025-47.","journal-title":"Blood"},{"key":"803_CR6","doi-asserted-by":"publisher","first-page":"5206","DOI":"10.1182\/blood-2025-5206","volume":"146","author":"A Mims","year":"2025","unstructured":"Mims A, Wei L, McLaughlin E, Jain J, Zeidner J, Odenike O, et al. Revumenib in combination with intensive induction and consolidation for newly diagnosed patients with NPM1-mutated or KMT2A-rearranged acute myeloid leukemia: preliminary results from the phase 1b etctn 10596 study. Blood. 2025;146:5206\u20135206. https:\/\/doi.org\/10.1182\/blood-2025-5206.","journal-title":"Blood"},{"key":"803_CR7","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1182\/blood-2025-3427","volume":"146","author":"U Borate","year":"2025","unstructured":"Borate U, Jain J, Huang Y, Dvorak-Kornaus K, Perl A, Zeidner J, et al. Preliminary results of A phase 1 study of the safety and tolerability of the combination of revumenib (REV) with gilteritinib (GILT) in relapsed\/refractory (R\/R) acute myeloid leukemia (AML). Blood. 2025;146:3427\u20133427. https:\/\/doi.org\/10.1182\/blood-2025-3427.","journal-title":"Blood"},{"key":"803_CR8","doi-asserted-by":"publisher","first-page":"5199","DOI":"10.1182\/blood-2025-5199","volume":"146","author":"H D\u00f6hner","year":"2025","unstructured":"D\u00f6hner H, Schuh A, Recher C, O\u2019Nions J, Aldoss I, Alfonso-Pierola A, et al. Bleximenib in combination with intensive chemotherapy: a phase 1b study in newly diagnosed acute myeloid leukemia with KMT2A or NPM1 alterations. Blood. 2025;146:5199\u20135199. https:\/\/doi.org\/10.1182\/blood-2025-5199.","journal-title":"Blood"},{"key":"803_CR9","doi-asserted-by":"publisher","first-page":"5200","DOI":"10.1182\/blood-2025-5200","volume":"146","author":"J O'Nions","year":"2025","unstructured":"O\u2019Nions J, Wei A, Esteve J, Aldoss I, Alfonso-Pierola A, Allred A, et al. Phase 1b study of bleximenib in combination with venetoclax in acute myeloid leukemia with KMT2A or NPM1 alterations. Blood. 2025;146:5200\u20135200. https:\/\/doi.org\/10.1182\/blood-2025-5200.","journal-title":"Blood"},{"key":"803_CR10","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.1182\/blood-2025-3429","volume":"146","author":"E Jabbour","year":"2025","unstructured":"Jabbour E, Sallman D, Briseno-Toomey D, Drenberg Guttke C, Huang X, Dillon R, et al. Camelot-2: a phase 3 randomized, double-blind, placebo-controlled, study of bleximenib, venetoclax and azacitidine for the treatment of participants with newly diagnosed acute myeloid leukemia harboring KMT2A rearrangements or NPM1 mutations, who are ineligible for intensive chemotherapy. Blood. 2025;146:3429\u20133429. https:\/\/doi.org\/10.1182\/blood-2025-3429.","journal-title":"Blood"},{"key":"803_CR11","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1182\/blood-2025-764","volume":"146","author":"G Issa","year":"2025","unstructured":"Issa G, Fathi A, Zeidan A, Erba H, Roboz G, Altman J, et al. Ziftomenib in combination with venetoclax and azacitidine in relapsed\/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a\/b safety and clinical activity results from KOMET-007. Blood. 2025;146:764\u2013764. https:\/\/doi.org\/10.1182\/blood-2025-764.","journal-title":"Blood"},{"key":"803_CR12","doi-asserted-by":"publisher","first-page":"3428","DOI":"10.1182\/blood-2025-3428","volume":"146","author":"G Issa","year":"2025","unstructured":"Issa G, Kantarjian H, Yilmaz M, Short N, Kadia T, El Hajjar G, et al. Phase l dose escalation and expansion of ziftomenib in combination with quizartinib in AML. Blood. 2025;146:3428\u20133428. https:\/\/doi.org\/10.1182\/blood-2025-3428.","journal-title":"Blood"},{"key":"803_CR13","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1182\/blood-2025-763","volume":"146","author":"N Daver","year":"2025","unstructured":"Daver N, Zeidner J, Watts J, Yuda J, Levis M, Montesinos P, et al. Monotherapy update from Phase 1 portion in Phase 1\/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia. Blood. 2025;146:763\u2013763. https:\/\/doi.org\/10.1182\/blood-2025-763.","journal-title":"Blood"},{"key":"803_CR14","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1182\/blood-2025-765","volume":"146","author":"J Watts","year":"2025","unstructured":"Watts J, Borate U, Levis M, Abaza Y, Wang E, Zeidner J, et al. Preliminary data from the ongoing Phase 1 study of the menin-MLL inhibitor enzomenib (DSP-5336) in combination with venetoclax and azacitidine in patients with relapsed or refractory acute myeloid leukemia. Blood. 2025;146:765\u2013765. https:\/\/doi.org\/10.1182\/blood-2025-765.","journal-title":"Blood"},{"key":"803_CR15","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1182\/bloodadvances.2025018178","volume":"10","author":"KK Chin","year":"2026","unstructured":"Chin KK, Ball BJ, Abaza Y, Altman JK, Thakur RK, Ali M, et al. Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure. Blood Adv. 2026;10:1537\u201347. https:\/\/doi.org\/10.1182\/bloodadvances.2025018178.","journal-title":"Blood Adv"},{"key":"803_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-026-02959-6","author":"K-K Chin","year":"2026","unstructured":"Chin K-K, Abdul-Hay M, Shukla M, Geyer MB, Tamari R, Ko KH, et al. Overcoming MEN1-mediated resistance with menin inhibitor switching in KMT2A-rearranged acute myeloid leukemia. Leukemia. 2026. https:\/\/doi.org\/10.1038\/s41375-026-02959-6.","journal-title":"Leukemia"},{"key":"803_CR17","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/bjh.70225","volume":"208","author":"M Thomas","year":"2026","unstructured":"Thomas M, Johnston H, Dworkin E, Wesevich A, Roloff GW, Saygin C, et al. Outcomes of patients with relapsed\/refractory acute leukaemia treated with revumenib with a focus on post-revumenib therapies. Br J Haematol. 2026;208:343\u20137. https:\/\/doi.org\/10.1111\/bjh.70225.","journal-title":"Br J Haematol"}],"container-title":["Experimental Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00803-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-026-00803-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00803-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T09:30:17Z","timestamp":1781861417000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40164-026-00803-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["803"],"URL":"https:\/\/doi.org\/10.1186\/s40164-026-00803-2","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"8 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors approved the manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}